J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Rezatopopt sees a path forward after all
Pivotal data set the stage for slightly delayed US accelerated approval filing.
J&J’s bladder hope gets its first approval
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
World Lung 2025 – cell therapy makes a cautious start against DLL3
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
